This company develops proprietary causal genome datasets that map genetic loci to downstream effects on biomarker levels and disease risk. They utilize AI-driven causal modeling to accurately predict drug efficacy and identify optimal indications for novel drug assets. Their platform supports biopharma partners in drug and target discovery, leading to successful licensing and funding outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
The traditional drug discovery process often struggles with accurately predicting drug efficacy and identifying optimal therapeutic indications, leading to costly failures in preclinical and clinical development. This inefficiency hinders the progression of promising drug assets and delays the delivery of new treatments to patients.
Solution
Biotx develops a proprietary causal genome dataset that maps genetic loci to their downstream effects on biomarkers and disease risk. This comprehensive dataset powers AI-driven causal modeling, enabling precise prediction of drug efficacy and the identification of the most suitable indications for novel drug assets. By leveraging large-scale human genetic data, Biotx provides biopharmaceutical partners with a data-driven approach to de-risk drug development and accelerate the identification of successful therapeutic strategies. This methodology has supported successful funding rounds for partners even when traditional preclinical and animal data were inconclusive.
Target Audience
Biotx serves biopharmaceutical companies, contract research organizations (CROs), and entities involved in pharma licensing and drug development.
Features
- Proprietary causal genome dataset mapping genetic loci to biomarker levels and disease risk.
- AI-driven causal modeling for accurate drug efficacy prediction.
- Identification of optimal indications for drug assets.
- Support for drug and target discovery through causal analysis.
- Data-driven approach to de-risk drug development pipelines.